Sharenet Sites 
Sharenet Sites
Notification of major interest in Mediclinic International plc shares
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
28 November 2017
Notification of Major Interest in Mediclinic International plc shares
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached (ii): Mediclinic International plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name Genesis Asset Managers, LLP
City and country of registered office (if applicable) St. Peter Port, Guernsey
4. Full name of shareholder(s) (if different from 3.)
Name N/A
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or
reached: 27th November 2017
6. Date on which issuer notified (DD/MM/YYYY): 28th November
7. Total positions of person(s) subject to the notification obligation
% of voting rights
% of voting rights through financial Total of both in % Total number of
attached to shares instruments (8.A + 8.B) voting rights of
(total of 8. A) (total of 8.B 1 + 8.B 2) issuer
Resulting situation
on the date on
which threshold 5.15% 5.15% 737,243,810
was crossed or
reached
Position of previ-
ous notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or
reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if possi- Direct Indirect Direct Indirect
ble) (Art 9 of Directive (Art 10 of Di- (Art 9 of Directive (Art 10 of Di-
2004/109/EC) rective 2004/109/EC) rective
(DTR5.1) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.2.1) (DTR5.2.1)
GB00B8HX8Z88 37,989,258 5.15%
SUBTOTAL 8. A 37,989,258 5.15%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Number of voting
Expira- rights that may be
Type of financial tion Exercise/ acquired if the instru- % of voting
instrument date Conversion Period ment is exercised/converted. rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))
Exercise/ Physical or
Type of finan- Expiration Conversion cash Number of % of voting
cial instrument date Period settlement voting rights rights
SUBTOTAL
8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or indirectly an interest in the (under-
lying) issuer
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal
entity(xiv) (please add additional rows as necessary)
% of voting rights
% of voting rights if it through financial in- Total of both if it
equals or is higher struments if it equals equals or is higher
than the notifiable or is higher than the than the notifiable
Name threshold notifiable threshold threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information
Place of completion London, England
Date of completion 28TH November 2017
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.
For further information please contact:
Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Company Secretary, Link Company Matters Limited
Victoria Dalby
+44 (0)207 954 9600
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
4
Date: 29/11/2017 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
